> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GSK Opens Phase 3 Asthma Study Using Anti-IL-5 Treatment
- URL: https://www.fdaweb.com/gsk-opens-phase-3-asthma-study-using-anti-il-5-treatment/
- Published: 2021-03-18T12:00:00.000Z
- Updated: 2026-09-14T16:51:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148917

GlaxoSmithKline says the first patient has been dosed in its SWIFT-2 trial as part of a Phase 3 clinical program investigating the safety and efficacy of GSK’294 in severe eosinophilic asthma (SEA). A company [statement](https://www.gsk.com/en-gb/media/press-releases/gsk-starts-the-first-phase-3-study-with-a-long-acting-anti-il-5-treatment-for-patients-with-severe-asthma/?ref=fdaweb.com) says GSK’294 is an investigational medicine with the potential to become the first biologic to deliver long-acting suppression of IL-5 in patients with SEA from one subcutaneous injection every six months.

The statement says GSK’294 has progressed from Phase 1 to Phase 3 studies in 3.5 years. The planned Phase 3 program will include 2,450 patients in three studies assessing the drug’s safety and efficacy, it says.